In contrast to these prior investigations, our multi-center and multi-stage validation is the first to evaluate the diagnostic value of BIRC5 autoantibody specifically in ANHCC and its complementary role alongside AFP diagnosis for HCC. This evidence concerns the gene BIRC5 and hepatocellular carcinoma.